Ken Song, RayzeBio CEO

September 13, 2022 11:17 AM EDTUpdated September 14, 04:18 AM

With fresh $160M, RayzeBio plots sprint through the clinic for lead radiopharmaceutical program — building on Novartis' success

Amber Tong

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER

ENDPOINTS CAREERS

VP, Clinical Development / CMO / CDO‬ ‭ (Stealth Portfolio Company)

Autonomy Bio Inc.

San Francisco, CA 94107, USA

view job offer post your job now

TRENDING NOW

Regeneron makes $80M obesity deal with Hansoh

Kymera unveils ‘exceptional’ Phase 1 data for its Dupixent-in-a-pill program

Phase 3 or bust: Why Lilly won't run mid-stage cancer trials

FDA approves Moderna’s next-gen Covid vaccine, with limits on most healthy people

Bristol Myers bets $1.5B on BioNTech's PD-L1xVEGF from Biotheus

sponsored

Cytiva and EurekaBio form strategic partnership to advance lentiviral vector manufacturing for cell and gene therapy ...